The Pharmaceutical Research and Manufacturers of America’s (PhRMA) new plan for conveying information about drug costs to consumers may be viewed as a defensive moved aimed at heading off a regulatory requirement to include list prices in direct-to-consumer (DTC) advertising. However, given the potential constitutional concerns inherent with any regulatory requirement, PhRMA’s voluntary approach might just be the one that ultimately prevails.
The voluntarily program also allows PhRMA to continue to shape the drug pricing conversation by framing the impact that other players in the healthcare supply chain have on the costs that consumers ultimately pay at the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?